Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
At a maximum tolerated dose of 5mm/kg cells, interim results in this phase 1 trial of the immunotherapeutic agent LCAR-B38M (Legend Biotech) CAR-T targeting B cell maturation antigen in multiple myeloma include 100% ORR, with 18 pts reaching CR or near CR status.
Multiple myeloma currently incurable.
Chimeric Antigen Receptor engineered T cell (CAR-T) has been effective targeting the B-cell biomarker CD19 in acute lymphblastic leukemia.
Trial to be expanded to ~100 patients.
Single arm interventional trial in China to assess safety and efficacy of LCAR-B38M CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.
Investigational drug targets antigen which plays a role in disease progression.
T cells harvested and "reprogrammed" with an artificially designed gene which seeks and destroys cancer cells.
Funding: Legend Biotech, Nanjing, China
(N=100 estimated total enrollment); interim results on first 35 patients.
Objective Response Rate (ORR) 100%; 33/35 had evident clinical remission (CR), very good partial response (VGPR), or PR within 2 months.